

NIFTYKEY LEVELS

Support 1: 9445 Support 2: 9390 Resistance1: 9700 Resistance2: 9850

Events Today

Results

APOLLOTRI

ECOM

HINDUNILVR

LAURUSLABS

POWERINDIA

SIS

TECHM

UGROCAP

XTGLOBAL

RELIANCE



Market Outlook

Yesterday, Nifty opened positive at 9408.60 and made a low of 9392.35. From there it moved towards the high of 9599.85 and closed positive at 9553.35 levels. Broader selling was seen in PHARMA and FMCG sector, while rest of the indices traded with positive bias. India VIX closed negative by 4.29% at 33.83.

Recent surge is largely reflecting buoyancy on the local front despite increasing number of cases in india. The breakout in the benchmark index, after few days of congestion phase, has further boosted sentiment. Formation of bullish candle on the daily scale indicates upbeat sentiment. As of now, it needs to hold above 9445 to witness an upmove towards 9700 and then 9850 levels. Overall setup and momentum seems to be positive and a hold of recent levels could extend rally, while support exists at 9445 and then 9390 levels.

Indian Market				
Index (Prev. Close)	Value	% Change		
SENSEX	32,720.16	1.89%		
NIFTY	9,553.35	1.84%		
BANK NIFTY	21,090.00	2.03%		
Global	Market			
Index (Prev. Close)	Value	% Change		
DOW	24,633.86	2.21%		
NASDAQ	8,914.71	3.57%		
CAC	4,671.11	2.22%		
DAX	11,107.74	2.89%		
FTSE	6,115.25	2.63%		
EW ALL SHARE	15,952.86	1.31%		
Morning Asian Market (8:30 am)				
SGX NIFTY	9,717.50	1.97%		
NIKKIE	20,280.00	2.57%		
HANG SENG	24,643.59	0.28%		
Commodi	ty Market			
Commodity(Prev. Close)	Value	% Change		
GOLD	45,546.00	-1.13%		
SILVER	41,775.00	0.15%		
CRUDEOIL	25.34	5.28%		
NATURALGAS	143.30	-4.21%		
Currency Market				
Currency (Prev. Close)	Value	% Change		
RS./DOLLAR	75.67	-0.68%		
RS./EURO	82.26	-0.50%		
RS./POUND	94.20	-0.84%		

Bond Yield					
Bond yield (Prev. Close)	Value	% Change			
G-sec 10YR : IND	6.13	-0.20%			

% Change in 1 day

Institutional Turnover					
FI	ı				
Buy(Cr.)	Sale(Cr.)	Net(Cr.)			
5734	5012	722			
113691	120869	(7178)			
491301	582392	(91091)			
DI	I .				
Buy(Cr.)	Sale(Cr.)	Net(Cr.)			
4304	4225	79			
68439	69843	(1404)			
416739	341028	75711			
	FI Buy(Cr.) 5734 113691 491301 DI Buy(Cr.) 4304 68439	FII Buy(Cr.) Sale(Cr.) 5734 5012 113691 120869 491301 582392 DII Buy(Cr.) Sale(Cr.) 4304 4225 68439 69843			

Quote of the Day: "Spend each day trying to be a little wiser than you were when you woke up

Please refer to page pg 05 for Bulk deals, Dividends, Bonus, Spilts, Buyback.



AXISBANK BUY 29-Apr-20

Loan book Growth for the bank was resilient among the tough time for the industry, Liability franchise also grew strong. Asset quality during the quarter improved with lower slippages. The NII growth was strong backed by improving NIM. Profitablity was impacted on account of the additional provisions worth Rs 3000 Cr made towards the COVID19. The PCR of the banks stands at 69% up from 62% in FY19. Bank has healthy Tier 1 of around 17.5% which can be used for growth however management has guided amid the uncertain circumstances they would look for capital conservation rather than chasing the growth. Going forward into FY21 the profitability of the bank is expected to be impacted on account of Higher provisioning requirements and lower fee income. The stock is currently trading at 1.51XFY20BV.We maintain BUY with TP of 586

MINDTREE ACCUMULATE 28-Apr-20

Mind tree exited FY20 with better revenue and margin performance.4Q revenue came at 1.9% with the highest ever deal win(USD393million in 4Q) despite Covid crisis. Even margin improved steadily (179bps)for last 3 quarters reflecting new leadership strategy working in right direction .Going forward we expect mind tree to be better placed among Mid cap in medium term primarily with strong growth visibility in Hi tech and CPG , Healthy pipeline & ramp up of large deal win(FY20 TCV stood at 1.2billion) and better operational execution. However since the company has some exposure in Travel & Hospitality (16.2% of rev).which will drag growth in near term. Post result, seeing the strong deal closure we have revised our target price from Rs 753 to 945. Thus we valued the stock with revised target price of Rs 945 and Recommend Accumulate.

AMBUJACEM NEUTRAL 28-Apr-20

AMBUJACEM volumes de-grew by 7% YoY with realization growth of 2.4% QoQ. However, the volumes in the last week of 1QCY20 remained impacted due to shut down of factories nationwide. The company has started its operation on a limited capacity in several plants but demand, supply chain and labor availability still remains the concern. On a medium term we expect demand to remain concern due to closure of all economic activities while prices are expected to remain in the same level for at least few months. On Capacity expansion front (4.5 MTPA at Marwar, Mundwa, Rajasthan) the company may delay the commercial production as the existing capacity will remain unutilized due to prevailing situation. On Margin front, the company's continuous thrust on running the plants efficiently, fossil fuel substitution with alternative fuel and emphasis on reducing logistic cost through supply chain efficiency will ensure savings from power & fuel and freight cost which will further contribute in improving EBITDA margin; Thus, we remain positive on the stock. However, considering the current scenario of lockdown and increasing rate of spread of disease, we expect the lockdown to extend which will hamper demand further. Thus, maintain our NEUTRAL rating with a target price of Rs. 190

INDUSINDBANK NEUTRAL 28-Apr-20

Moderation in loan growth continued during the quarter along with the deterioration of asset quality on account of the elevated slippages from the stressed sectors. The NII growth was strong led by improvement in NIM with reduction in the cost of funds. During the quarter bank witnessed withdrawal of deposits by the state government which led in sequential fall of deposits. The management has guided for moderation in corporate loan growth. The exposure to stressed sectors like telecom and microfinance might require heavy provisioning thus denting the profitability. The stock is currently trading at 0.83XFY20BV. We maintain Neutral with TP of 547.

APLLTD ACCUMULATE 24-Apr-20

APLLTD continued to grow strongly in 4QFY20 largely driven by robust growth in US and India partly offset by weak API. Being in the essential services sector, the company has been least impacted by the disruption caused due to Covid'19. Going forward, with 10 expected launches in H1FY21 in the US market, strong ramp up in the domestic sales with major focus on prescription driven sales and 15% expected growth in API sales over FY20 – we expect a strong traction in FY21. The long term prospects of the company looks promising based on the commissioning of the new facilities (complex generics), for which the meaningful contribution is expected from FY22 onwards. Though the margins will be under pressure due to increase in R&D cost and operational cost on account of commissioning of these new facilities. Therefore, we maintain our ACCUMULATE rating on the stock with the target price of Rs.780.



Stock In News

	SIDBI extends loan repayment term to 1-year for NBFCs, MFIs: Small Industries Development Bank of India (SIDBI) has
	extended the repayment period of loans to non-banking finance companies (NBFCs) and Microfinance Institutions (MFIs),
	announced under Reserve Bank of India's (RBI) special liquidity scheme, to one year from the 90-day period earlier. This is
	a significant development as microlenders felt the earlier repayment rules were stringent considering the present
	operating environment. Due to COVID-19 induced lockdown, operations of these firms have come to a halt. Most MFIs
	and NBFCs felt that they will not have enough time to make repayments to SIDBI in just 90 days.
П	Bharti Airtel: Clarified that it has renewed its relationship with Nokia to boost its network capacity and customer
_	experience and the announcement in this regard was made by Nokia only.
П	TD Power Systems: Has partially resumed its operations.
	Tata Motors: Jaguar Land Rover has restored three-fourth of its budgeted production in China, as reported by Bloomberg
_	News
П	M&M Financial Services: Manulife Investment Management (Singapore) acquired 49 percent stake in the company's two
_	wholly-owned arms Mahindra Asset Management and Mahindra Trustee. Share Agreement was executed on June 21,
	2019. Manulife has invested Rs 265 crore in the 51:49 joint venture.
П	Wipro: The company and Nutanix will launch digital database services (DDS) powered by Nutanix Era and Nutanix HCI
_	software.
_	Vodafone Idea: The Supreme Court has directed the Income-Tax Department to refund an amount of Rs 733 crore to the
	company within 4 weeks.
ч	Suven Pharmaceuticals: The company has clarified that the damages to all the equipment, furniture & fixtures due to fire
	in R&D labs in Jeedimetla Unit is estimated around Rs 18 crore and were fully insured.
	Lupin gets USFDA nod for generic inhalation solution
	HUL: Glaxo plans sale of \$3.7 billion stake in Hindustan Unilever
Ц	Reliance Industries Ltd (RIL) has increased its stake in US-based SkyTran Inc, a venture-funded technology company that
	develops pod car transport systems. In a stock exchange filing, RIL said it has raised its holding in SkyTran to 26.31% from
	17 37% on a fully-diluted hasis

Red: Negative Impact Green: Positive Impact Black: Neutral.



Management Interview

BAJAJ-AUTO Management Interview

☐ The company will resume operations at plants only when dealerships open up, and it is expected to operate at about 50% capacity (i.e. 200,000 vehicles) next month.
☐ Chakan plant outside Pune has not received nod for production, which is unfortunate as that is the company's main export plant. "However, yesterday it received permission to shift goods from there.
☐ In the month of April, because of exports, it will see sales of something like 30,000-35,000 number. Again the majority would be for exports.
☐ In June, it is hoping to record something in excess of 250,000 vehicles, i.e. two-third capacity.
□ Cost cutting measures: It has already implemented almost all of the cost cutting measures. It will save between Rs 150-200 crore this year.
☐ However, there are no plans to cut jobs and it is not going to cut jobs at this stage.
MARICO Management Interview:
☐ The companies most of the factories are open with reduced labour force while the supply chain is still getting settled. Thus expects once things normalise, the recovery will be quite significant.
☐ The Company has started exploring some health and hygiene products , opportunities in some new areas in food and also looking to push innovations in the discretionary segment.
□ Due to COVID-19, the company is extremely aggressive in terms of cutting extra expenditure like travel, out-of-home advertising and the savings from same is being used to ensure that there is no loss of jobs and continue to support some of the third party ecosystem ensuring payment in time.
☐ The Company's market share is protected. Thus, conserving A&P significantly especially in the discretionary part of the portfolio and as and when things normalise, will invest the same and gain market share.
☐ The Management is expecting significant changes in terms of shopping and consumption habits expected in next financial year. Some are enumerated below:
 Management expects significant movement into staples, health and hygiene, immunity and items of daily consumption in post COVID world. Therefore leader brands will likely to take pole position and gain market share, especially those with strong distribution and equity.
 Management also expects significant shift from out-of-home consumption to in-home consumption. Therefore, even things like ready-to-eat, ready-to-cook products are likely to be consumed far more.
 Expects less spending on things like eating out, entertainment, travel, home improvement and autos. Pricing and providing value to the consumer is extremely important as people could have less disposable income in the immediate quarters post Covid outbreak.
<u>HEROMOTOCO</u>
☐ The company has announced a financial package for its dealer partners to help them improve their profitability and liquidity situation in COVID-19 crisis.
☐ It will be effective from May 1, 2020 and includes a revised pricing structure on new products, financial support towards
the interest on dealer stocks and convenient financing options from Hero FinCorp. The company has revised the pricing structure that will enhance its profitability, and the new structure will be applicable
on all dispatches post the lockdown. This package will translate into higher margins per vehicle.
☐ The management also announced financial support towards the interest on the dealer stock for the complete lockdown period of 41 days.

☐ According to dealers, the Company has also come up with a robust action plan for re-opening of business for dealers

once the lockdown is lifted.





	BULK DEAL						
EXCHANGE	Date	SECURITY CODE	CLIENT NAME	DEAL TYPE	QUANTITY	PRICE	
NSE	29-04-20	CYIENT	AMANSA HOLDINGS PRIVATE LIMITED	BUY	21,11,780	205	
NSE	29-04-20	CYIENT	T.ROWE PRICE INTERNATIONAL DISCOVERY FUND (IDF)	SELL	30,12,457	207.02	
NSE	29-04-20	EQUITAS	DIVYA PORTFOLIO PRIVATE LIMITED	BUY	20,63,753	53.71	
NSE	29-04-20	EQUITAS	DIVYA PORTFOLIO PRIVATE LIMITED	SELL	19,61,753	53.76	
NSE	29-04-20	EQUITAS	TOWER RESEARCH CAPITAL MARKETS INDIA PRIVATE LIMITED	BUY	20,80,178	53.78	
NSE	29-04-20	EQUITAS	TOWER RESEARCH CAPITAL MARKETS INDIA PRIVATE LIMITED	SELL	20,80,178	53.58	
NSE	29-04-20	EROSMEDIA	ALPHA LEON ENTERPRISES LLP	BUY	5,30,349	18.65	
NSE	29-04-20	EROSMEDIA	ALPHA LEON ENTERPRISES LLP	SELL	3,44,212	18.76	
NSE	29-04-20	IBULHSGFIN	ALPHAGREP SECURITIES PRIVATE LIMITED	BUY	22,60,120	127.35	
NSE	29-04-20	IBULHSGFIN	ALPHAGREP SECURITIES PRIVATE LIMITED	SELL	22,60,120	127.41	
NSE	29-04-20	IBULHSGFIN	GRAVITON RESEARCH CAPITAL LLP	BUY	49,13,215	127.18	
NSE	29-04-20	IBULHSGFIN	GRAVITON RESEARCH CAPITAL LLP	SELL	49,13,215	127.21	
NSE	29-04-20	IBULHSGFIN	TOWER RESEARCH CAPITAL MARKETS INDIA PRIVATE LIMITED	BUY	58,47,933	127.14	
NSE	29-04-20	IBULHSGFIN	TOWER RESEARCH CAPITAL MARKETS INDIA PRIVATE LIMITED	SELL	58,64,060	127.53	
NSE	29-04-20	RBLBANK	BNP PARIBAS ARBITRAGE	BUY	29,79,801	125.42	
NSE	29-04-20	RBLBANK	TOWER RESEARCH CAPITAL MARKETS INDIA PRIVATE LIMITED	BUY	29,46,586	123.56	
NSE	29-04-20	RBLBANK	TOWER RESEARCH CAPITAL MARKETS INDIA PRIVATE LIMITED	SELL	30,06,944	123.6	
NSE	29-04-20	RNAVAL	ALPHA LEON ENTERPRISES LLP	BUY	65,32,284	1.25	
NSE	29-04-20	RNAVAL	ALPHA LEON ENTERPRISES LLP	SELL	17,12,700	1.26	
NSE	29-04-20	RNAVAL	YES BANK LTD SELL		90,86,167	1.28	
NSE	29-04-20	SANCO	RESOURCE OPZIONE CONSULTANCY PRIVATE LIMITED BUY 10,000		8.78		
NSE	29-04-20	SANCO	RESOURCE OPZIONE CONSULTANCY PRIVATE LIMITED SELL 84,000 7.		7.76		
NSE	29-04-20	SINTEX	ALPHA LEON ENTERPRISES LLP BUY 35,27,564 0.9.		0.95		

Corporate Action					
EXCHANGE SECURITY CODE SECURITY NAME EX- DATE PURPOSE RECORD DATE					
BSE	500092	CRISIL	04-05-20	Interim Dividend - Rs 6.0000	05-05-20





PARTICIPANT WISE OPEN INTEREST





MARKET MOVERS (1 MONTH CHANGE)







Result Calendar Q3FY20					
BSE Code	Company Name	Result Date	BSE Code	Company Name	Result Date
533096	ADANIPOWER	27-Apr-20	534758	CIGNITI	07-May-20
500425	AMBUJACEM	27-Apr-20	532175	CYIENT	07-May-20
540777	HDFCLIFE	27-Apr-20	532281	HCLTECH	07-May-20
532187	INDUSINDBK	27-Apr-20	500790	NESTLEIND	12-May-20
532663	SASKEN	27-Apr-20	500338	PRSMJOHNSN	12-May-20
532215	AXISBANK	28-Apr-20	539268	SYNGENE	12-May-20
532129	HEXAWARE	29-Apr-20	500002	ABB	13-May-20
538566	APOLLOTRI	30-Apr-20	500124	DRREDDY	13-May-20
531533	ECOM	30-Apr-20	505890	KENNAMET	13-May-20
500696	HINDUNILVR	30-Apr-20	526299	MPHASIS	13-May-20
540222	LAURUSLABS	30-Apr-20	532523	BIOCON	14-May-20
543187	POWERINDIA	30-Apr-20	532988	RANEENGINE	18-May-20
540673	SIS	30-Apr-20	500307	NIRLON	19-May-20
532755	TECHM	30-Apr-20	532987	RBL	19-May-20
511742	UGROCAP	30-Apr-20	532349	TCI	19-May-20
531225	XTGLOBAL	30-Apr-20	532661	RML	20-May-20
531869	SACHEMT	01-May-20	505800	RANEHOLDIN	27-May-20
540716	ICICIGI	02-May-20	524038	VENLONENT	30-May-20
533179	PERSISTENT	05-May-20	539447	BEARDSELL	25-Jun-20



	Economic Calendar				
Country	Monday 27th April 2020	Tuesday 28th April 2020	Wednesday 29th April 2020	Thursday 30th April 2020	Friday 01st May 2020
us		Retail Inventories Ex Auto, Goods Trade Balance, CB Consumer Confidence	API Weekly Crude Oil Stock, GDP, Crude Oil Inventories, Fed Interest Rate Decision		Manufacturing PMI, U.S. Baker Hughes Total Rig Count
UK/EUROPE				CPI, GDP, Unemployment Rate, ECB Interest Rate Decision	
INDIA					Holiday India - Maharashtra Day, FX Reserves, USD

Narnolia Financial Advisors Ltd. is a SEBI registered Research Analyst having SEBI Registration No. INH300006500. The Company/Analyst (s) does/do not have any holding in the stocks discussed but these stocks may have been recommended to clients in the past. Clients of Narnolia Financial Advisors Ltd. may be holding aforesaid stocks.

The stocks recommended are based on our analysis which is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed.

<u>Disclosures</u>: Narnolia Financial Advisors Ltd. (NFAL) (FormerlyMicrosec Capital Ltd.) is a SEBI Registered Research Analyst having registration no. INH300006500. NFALis engaged in the business of providing Stock Broking, Depository Participant, Merchant Banking, Portfolio Management & distribution of various financial products. Details of associate entities of NFAL is available on the website at www.narnolia.com

No penalties have been levied on NFAL by any Regulatory/Statutory authority. NFAL, it's associates, Research Analyst or their relative may have financial interest in the subject company. NFAL and/or its associates and/or Research Analyst may have beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report, NFAL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of NFAL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report. Research Analyst may have served as director/officer, etc. in the subject company in the last 12 month, period, NFAL and/or its associates may have received compensation from the subject company in the past 12 months. In the last 12 months period ending on the last day of the month immediately preceding the date of publication of this research report, NFAL or any of its associates may have; a) managed or co-managed public offering of securities from subject company of this research report, b) received compensation for investment banking or merchant banking or brokerage services from subject company of this research report, c) received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report, d) Subject Company may have been a client of NFAL or its associates during 12 months preceding the date of distribution of the research report. NFAL and it's associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. NFAL and / or its affiliates may do and seek to do business including Investment Banking with companies covered in the research reports. As a result, the recipients of this report should be aware that NFAL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific Merchant Banking, Investment Banking or Brokerage service transactions. Research Analyst's views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of NFAL or its associates maintains arm's length distance with Research Team as all the activities are segregated from NFAL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Analyst Certification The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement-

Analyst's ownership of the stocks mentioned in the Report	NIL

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com.

Correspondence Office Address: Arch Waterfront, 5th Floor, Block GP, Saltlake, Sector 5, Kolkata 700 091; Tel No.: 033-40541700; www.narnolia.com.

Registered Office Address: Marble Arch, Office 201, 2nd Floor, 236B, AJC Bose Road, Kolkata 700 020; Tel No.: 033-4050 1500; www.narnolia.com

Compliance Officer: Manish Kr Agarwal, Email Id: mkagarwal@narnolia.com, Contact No.:033-40541700.

Registration details of Company: Narnolia Financial Advisors Ltd. (NFAL): SEBI Stock Broker Registration: INZ000166737 (NSE/BSE/MSEI); NSDL/CDSL: IN-DP-380-2018; Research Analyst: INH300006500, Merchant Banking: (Registration No.: INM000010791), PMS: (Registration No.: INP000002304), AMFI Registered Mutual Fund distributor: ARN 3087

Registration Details of Group entities: G. Raj & Company Consultants Ltd (G RAJ)-BSE Broker INZ260010731; NSDL DP: IN-DP-NSDL-371-2014 || Narnolia Commerze Limited (Formerly Microsec Commerze Ltd.)-MCX/NCDEX Commodities Broker: INZ000051636 || NarnoliaVelox Advisory Ltd. - SEBI Registered PMS: INP000005109 || Eastwind Capital Advisors Pvt Ltd. (EASTWIND)-SEBI Registered Investment Adviser: INA300005439 || Narnolia Insurance Brokers Limited (Formerly Microsec Insurance Brokers Ltd.)-IRDA Licensed Direct Insurance Broker (Life & Non-Life) Certificate No. 134, License No. DB046/02 || Narnolia Securities Ltd. (NSL)-AMFI Registered Mutual Fund distributor: ARN 20558, PFRDA NPS POP: 27092018 || Narnolia Capital Advisors Pvt. Ltd. - RBI Registered NBFC:B.05.02568.

Disclaimer:

This report has been prepared by Narnolia Financial Advisors Ltd. (NFAL)and is meant for sole use by the recipient and not for public circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of NFAL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should con

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NFAL & its group companies to registration or licensing requirements within such jurisdictions.